InvestSMART

Epiminder Limited (ASX:EPI)

ALERT: Price-sensitive ASX Announcement for EPI
Current share price for EPI : $0.340 -0.52 (-60.47%)+
Announcement
Release
25 Feb 2026 8:14AM
Price at Release
$0.860
Full Release
download
Summary
Epiminder Limited's 1H FY26 Results Presentation highlights significant progress in its DETECT demonstration program and development of the next-generation Minder® device. The company emphasizes the device's potential in providing valuable long-term EEG monitoring, addressing unmet needs in epilepsy care. Despite recording a net income loss, Epiminder maintains robust cash reserves post-IPO, ensuring sufficient funding for ongoing operations and future developments. The company's strategy includes generating early revenue opportunities and penetrating the US market through the DETECT program, targeting a market potential of US$1.1 billion annually.
Key Points
  • Epiminder's Minder® device provides long-term EEG monitoring for epilepsy care.
  • 1H FY26 operational highlights include onboarding 9 of 25 DETECT sites and completing next-gen device hardware design.
  • The DETECT program aims to demonstrate cost-effectiveness and clinical value in the US.
  • Minder® is the first FDA authorised sub-scalp EEG device, with a market potential of up to US$1.1 billion annually.
  • Financially, Epiminder recorded a net income loss but maintains a strong cash position post-IPO.
  • Cash reserves are projected to support operations and development plans until CY28.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.